Novartis Extends Tender Offer for Eon Labs, Inc. Through July 1, 2005
21. Juni 2005 07:00 ET
|
Novartis
BASEL, Switzerland, June 21, 2005 (PRIMEZONE) -- Novartis announced today that Zodnas Acquisition Corp., an indirect wholly owned subsidiary of Novartis, is extending its cash tender offer to acquire...
Novartis Announces Completion of Hexal AG Acquisition, Integrates Company With Sandoz
07. Juni 2005 01:31 ET
|
Novartis
BASEL, Switzerland, June 7, 2005 (PRIMEZONE) -- Novartis (NYSE:NVS) announced today the completion of its acquisition of the generic pharmaceutical company Hexal AG in Germany on June 6. The...
Novartis Highlights Pharmaceutical Research Strategy, Intensifying Focus on Molecular Pathways Shared by Various Diseases
03. Mai 2005 01:30 ET
|
Novartis
-- Transforming the "grammar" of drug discovery by focusing on
molecular pathways and patient stratification
-- Redefining Research-to-Development transition through fast and
rigorous...
Novartis Files Exjade New Drug Applications for Treatment of Chronic Iron Overload Due to Blood Transfusions
03. Mai 2005 01:30 ET
|
Novartis
-- Innovative, once-a-day oral formulation offers life-altering
treatment option to broad range of iron overload patients
-- Filings based on data from largest prospective clinical trials
...
Novartis: New Study Finds Coartem (Artemether-Lumefantrine) is the Most Effective Malaria Treatment in Areas of High Resistance to Conventional Anti-Malarials
26. April 2005 11:57 ET
|
Novartis
- USD170 million financing commitment from Global Fund
will help secure the majority of 2005-2006 Coartem supply
- Novartis continues unprecedented production scale-up to
meet rapidly...
Novartis Continues to Outpace The Market, Delivering Strong First Quarter 2005 Sales and Earnings Growth
21. April 2005 01:15 ET
|
Novartis
BASEL, Switzerland, April 21, 2005 (PRIMEZONE) -- Novartis (NYSE:NVS): Key figures
First quarter
Q1 2005 Q1 2004 % Change
...
Novartis: PTK/ZK CONFIRM 1 Study Shows Positive Drug Effects in Phase III Study in Metastatic Colorectal Cancer, Filing Now Anticipated for Early 2007
21. März 2005 00:13 ET
|
Novartis
Pre-planned analysis of progression-free survival as assessed by
investigators achieved statistical significance while analysis of
primary endpoint of progression-free survival assessed by...
Novartis to Acquire Hexal AG and Eon Labs, Creating the World Leader
21. Februar 2005 01:30 ET
|
Novartis
-- Significantly broadened product portfolio
-- One of the largest pipelines in industry covering most generic
opportunities
-- Best-in-class development teams with proven record of being...
Novartis Obtains Rights from Otsuka to Develop New Treatment for Dry Eye
07. Februar 2005 01:30 ET
|
Novartis
-- Novel mechanism of action expected to enhance tear secretion and
increase mucin levels covering conjunctiva and cornea
-- Over 22 million patients visit ophthalmologists each year seeking...
Novartis Delivers Record Results With Strong Double-Digit Net Sales And Earnings Growth In 2004
20. Januar 2005 01:22 ET
|
Novartis
BASEL, Switzerland, Jan. 20, 2005 (PRIMEZONE) --Novartis (NYSE:NVS): Pharmaceuticals, led by the innovative, fast-growing oncology and cardiology franchises, drives expansion with market share...